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Hepatocyte nuclear factor (HNF)4a is a central regu-
latorofgeneexpression incell types thatplayacritical
role in metabolic homeostasis, including hepato-
cytes, enterocytes, and pancreatic b cells. Although
fatty acids were found to occupy the HNF4a ligand-
binding pocket and were proposed to act as ligands,
there is controversy about both the nature of HNF4a
ligands as well as the physiological role of the bind-
ing. Here, we report the discovery of potent synthetic
HNF4a antagonists through a high-throughput
screen for effectors of the human insulin promoter.
These molecules bound to HNF4a with high affinity
and modulated the expression of known HNF4a
target genes. Notably, they were found to be selec-
tively cytotoxic to cancer cell lines in vitro and in vivo,
although in vivo potency was limited by suboptimal
pharmacokinetic properties. The discovery of bioac-
tive modulators for HNF4a raises the possibility that
diseases involving HNF4a, such as diabetes and
cancer, might be amenable to pharmacologic inter-
vention by modulation of HNF4a activity.
INTRODUCTION
HNF4a is a member of the nuclear receptor (NR) superfamily of
transcription factors and binds as a homodimer to a relatively806 Chemistry & Biology 19, 806–818, July 27, 2012 ª2012 Elsevier Ldegenerate consensus DNA sequence consisting of two direct
repeats separated by one or two nucleotides (Bolotin et al.,
2010). It is expressed at high levels in hepatocytes, enterocytes,
pancreatic epithelial cells (including b cells), and renal tubular
epithelial cells (Drewes et al., 1996; Jiang et al., 2003). In these
cells, it sits at the heart of a transcriptional regulatory network
that controls the expression of many genes, but particularly
those involved in intermediary metabolism and maintenance of
epithelial differentiation.
Because of the important role of HNF4a in regulating
metabolic processes such as glucose and lipid homeostasis
(Hayhurst et al., 2001; Odom et al., 2004; Stoffel and Duncan,
1997) and the high percentage of pharmaceuticals that target
NR transcription factors, there has been a great interest in devel-
oping synthetic ligands for HNF4a (Hertz et al., 2001; Le Gue´vel
et al., 2009; Sladek, 2011). However, this has proven to be
difficult. Although medium- and long-chain fatty acids (MCFAs
and LCFAs, respectively) are invariably found bound in the
HNF4a ligand-binding pocket (LBP) in structural studies of
HNF4a purified from bacteria (Dhe-Paganon et al., 2002; Duda
et al., 2004), there has been little evidence that they modulate
HNF4a activity, and attempts to study how different fatty acids
affect the conformation of HNF4a have been stymied by the
fact that ligand exchange in vitro is very poor (Dhe-Paganon
et al., 2002; Wisely et al., 2002). This has raised questions about
the extent to which HNF4a function is regulated by ligand
binding, versus a model in which small molecules bound in the
ligand-binding pocket (LBP) play a structural role (Sladek, 2011).
Recently, linoleic acid was identified in the LBP of HNF4a puri-
fied from COS-7 cells. In vivo, linoleic acid was present in thetd All rights reserved
Figure 1. Identification of BIM5078, A Novel
Regulator of Insulin Gene Transcription
(A) High-throughput screen for compounds that
modulate insulin promoter activity in T6PNE. A sub-
set of the Chembridge DiverSet library of chemically
diverse small molecules was used in a screen of
T6PNE cells for compounds that modulated the
activity of a human insulin promoter-GFP transgene.
(B) BIM5078-mediated repression of insulin
promoter activity is dose dependent. T6PNE cells
were exposed to the indicated concentration of
BIM5078 for 48 hr. Effects of BIM5078 on the
exogenous insulin promoter in T6PNE is reported
as percentage of GFP+ cells, as determined by
imaging the green channel and normalizing to the
total number of cells per well. Endogenous insulin
promoter activity was probed through quantitative
real-time PCR (Q-PCR) for insulin and GAPDH
mRNA. Insulin mRNA values are reported as
normalized to GAPDH to control for nonspecific
compound effects. Values represent the mean ±
SE, n = 3. *p < 0.05, **p < 0.01, ***p < 0.001.
(C) Structural homology between BIM5078 and
PPARg agonist FK614.
(D) PPRE activation. HeLa cells were cotrans-
fected with the PPRE reporter plasmid PPRE-Luc
in the absence and presence of a PPARg expres-
sion vector. BIM5078 and FK614, but not BI6015,
activated PPRE-Luc in HeLa cells when co-
transfected with a PPARg expression vector.
Values represent the mean ± SE, n = 3. *p < 0.005.
(E) BIM5078 and BI6015 repressed endogenous
insulin mRNA (normalized to 18S rRNA). FK614
had no effect on endogenous insulin expression.
Values represent the mean ± SE, n = 3. *p < 0.05,
**p < 0.005, NS = no significance.
See also Table S1 and Figure S1.
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HNF4a AntagonistsLBP of HNF4a from mice that were in the fed state, yet was
absent in fastedmice, suggesting that ligand binding is regulated
(Yuan et al., 2009). A study inDrosophila species using anHNF4a
ligand-binding domain (LBD) sensor found that HNF4a LBD acti-
vation was highly modulated, although the nature of the ligand
remained undetermined (Palanker et al., 2009). Because of the
limited evidence indicating that ligand binding influences the
state of transcriptional activity mediated by HNF4a (Yuan
et al., 2009), studies of HNF4a have been restricted to genetic
deletion (Chen et al., 1994; Duncan et al., 1997; Gupta et al.,
2005; Hayhurst et al., 2001) or overexpression (Carter et al.,
1993; Harnish et al., 1996; Inoue et al., 2002).
Previously, we described an assay for insulin promoter modu-
lators based on a cell line derived from human fetal islets,
T6PNE, which was engineered to express the b cell transcription
factors PDX-1, NeuroD1, and E47 (as a fusion protein with
a modified estrogen receptor LBD to render it tamoxifen-induc-
ible; E47MER) (Kiselyuk et al., 2010). Induction of E47 by tamox-
ifen resulted in dose-responsive expression of the insulin gene,
as well as a number of other genes expressed in b cells.
T6PNE cells were adapted for high-throughput screening by
transduction with a lentiviral vector expressing green fluorescent
protein under the control of the human insulin promoter (Hao
et al., 2006).
Here, as part of a continuing effort to discover novel regulators
of the insulin promoter as tools to study diabetes, we used theChemistry & Biology 19,T6PNE insulin promoter assay to screen a diverse synthetic
chemical library. A screening hit, BIM5078, potently repressed
insulin expression in that assay. BIM5078 bound to HNF4a
with high affinity and modulated HNF4a target genes and meta-
bolic processes controlled by HNF4a. Interestingly, BIM5078
and a related analog, BI6015, were selectively cytotoxic to trans-
formed cells in vitro. In vivo, BI6015 induced apoptosis of
a human hepatocellular carcinoma cell line. Further development
of related compounds could lead to pharmacologic therapies for
a variety of diseases, including diabetes and cancer, as well as
provide a powerful tool for studying the physiological role of
HNF4a.
RESULTS
Identification of a Small Molecule Inhibitor of the Insulin
Promoter: BIM5078
To identify molecules with novel mechanisms of action on the
insulin promoter, a high-throughput screen of structurally diverse
compounds, consisting of a subset of the ChemBridge DiverSet
Library, was conducted for inhibition of the insulin promoter in
T6PNE cells (Kiselyuk et al., 2010) (Figure 1A; Table S1 available
online). As previously described, primary hits were subjected to
secondary counterscreens to assess potency on the endoge-
nous insulin promoter and the modified estrogen receptor
(Kiselyuk et al.) (Figure S1). From the screen, we identified one806–818, July 27, 2012 ª2012 Elsevier Ltd All rights reserved 807
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HNF4a Antagonistssmall molecule, 1-(20-chloro-50-nitrobenzenesulfonyl)-2-methyl-
benzimidazole, hereafter referred to as BIM5078, that passed
the counterscreen for lack of tamoxifen-like activity on the modi-
fied estrogen receptor (Kiselyuk et al., 2010), and exhibited
dose-responsive inhibition of endogenous insulin expression,
with an IC50 of 930 nM (Figure 1B).
BIM5078 Is Structurally Similar to FK614, a PPARg
Agonist
A major problem with cell-based phenotypic as opposed to
biochemical high-throughput screens is the difficulty in identifying
the precise molecular target of small molecules that have the
desired effect in the assay. To examine potential targets for
BIM5078, we conducted a chemoinformatic analysis of
BIM5078 that revealed structural similarity to an atypical PPARg
agonist, FK614, formerly evaluated as a therapeutic for type 2 dia-
betes (Fujimura et al., 2005) (Figure 1C). Accordingly, BIM5078
andFK614were tested in a PPAR response element (PPRE)-lucif-
erase reporter assay. Consistent with their structural similarity,
both BIM5078 and FK614 had activity as PPARg agonists (Fig-
ure 1D). BIM5078 activated the PPRE 2-fold, and activation was
enhanced nearly 4-fold by cotransfection with a PPARg expres-
sion vector (Figure 1D). Although both BIM5078 and FK614 were
potent PPARg agonists, FK614 had no effect on insulin promoter
activity (Figure 1E), suggesting that PPARg activation was not
responsible for the effect of BIM5078 on the insulin promoter. In
addition, no change in luciferase activity was found when PPARa
and PPARd were cotransfected in the PPRE-luciferase reporter
assay in the presence of BIM5078. Finally, as described in
more detail below, BI6015, a compound structurally related to
BIM5078, potently inhibited the insulin promoter but lacked
activity as a PPARg agonist (Figures 1D and 1E). Taken together,
these data suggested that the repressive effect of BIM5078 on
the insulin promoter was due to a target other than the PPARs.
BIM5078 Bound Directly to HNF4a and Interacted with
the LBP In Situ
The only transcription factor known to interact with PPREs other
than PPARs and their binding partner RXR is HNF4a (Nakshatri
and Bhat-Nakshatri, 1998; Nicolas-Frances et al., 2000; Winrow
et al., 1994), another member of the NR superfamily. Accord-
ingly, we measured the direct binding of BIM5078 and FK614
to HNF4a. Binding was determined using full-length HNF4a
and monitoring the intrinsic fluorescence of its aromatic amino
acids Tyr/Trp (Petrescu et al., 2002).
The resultant EC50 (± standard errors) were 11.9 ± 3.1 nM for
BIM5078 (Figure 2A) and 254 ± 56 nM for FK614 (Figure 2B).
Additional analysis of the data using the Hill equation demon-
strated that the Hill coefficient for BIM5078 was 0.9 ± 0.3 (i.e.,
close to unity), consistent with a single binding complex between
the compound and HNF4a. The value of the Hill coefficient for
FK614 was 0.6 ± 0.1, suggesting that FK614 was likely to have
an additional binding mode characterized by high-micromolar
affinity. To support this notion, we observed that the amplitude
of the fluorescence change (Fmax) in the FK614 binding curve
was almost double that of BIM5078, suggesting that some addi-
tional tryptophans might be affected upon FK614 binding. It is
possible that hydrophobic groups present on FK614 resulted in
nonspecific binding elsewhere on the surface of HNF4a.808 Chemistry & Biology 19, 806–818, July 27, 2012 ª2012 Elsevier LThe X-ray crystal structures of the human and rat HNF4a LBDs
were reported some time ago, and it was noted that free fatty
acids (FFAs) were always bound in the absence of exogenously
added ligand (Dhe-Paganon et al., 2002; Duda et al., 2004). Using
the crystal structure (PDB Code 1m7w), BIM5078 was docked
into the LBD of HNF4a using the GOLD docking algorithm (Jones
et al., 1997) (Figure 2D, tanmolecule in left panel). The high Gold-
Score (43.6) suggested that it is reasonable for BIM5078 to bind
in the LBP in a position similar to that of the putative endogenous
ligand (i.e., FFA). However, FK614, the PPARg agonist that does
not affect insulin promoter activity, did not dock well in the LBP
(GoldScore 20.8) (Figure 2D, green molecule in right panel). The
primary contributing factor to the poor docking was that signifi-
cant internal torsional strain was required for it to fit into the LBP.
BIM5078 Mediated Insulin Promoter Repression
through HNF4a
For HNF4a to be the target of BIM5078, it must be expressed in
T6PNE cells. To test this prediction, we conducted quantitative
RT-PCR for HNF4a in T6PNE cells. Although expressed at a
very low level at baseline, it was induced more than 40-fold by
E47 through tamoxifen administration in a saturable manner
(Figure 2E).
A further prediction of a model in which HNF4a acts on the
insulin promoter is that direct inhibition of HNF4a expression
by siRNA should inhibit insulin promoter activity. As predicted,
transfection of HNF4a siRNA into T6PNE cells led to potent inhi-
bition of insulin promoter activity both from the endogenous
promoter as well as from the human insulin promoter-eGFP
transgene (Figure 2F). Taken together, these data support the
notion that endogenous HNF4a may have a role in maintaining
the activation state of the human insulin promoter in T6PNE cells.
BIM5078 Affected the Expression of Known HNF4a
Target Genes
To provide additional evidence that BIM5078 inhibited HNF4a,
we examined its effect on known HNF4a target genes. HNF4a
autoregulates its own transcription through a complex feedback
loop between HNF4a and HNF1a, part of which involves direct
binding of HNF4a to its own promoter (Bailly et al., 2001). As pre-
dicted, BIM5078 potently repressed HNF4a expression in
T6PNE (Figure 3A), the murine insulinoma cell line MIN6 (Fig-
ure 3B), and in the HepG2 hepatoma line (Figure 3C), which
has exceptionally high levels of HNF4a expression.
We expanded the analysis of the effects of BIM5078 on gene
expression by performing global gene expression profiling of
T6PNE cells in the presence and absence of BIM5078 (GSE
33432). We previously showed that T6PNE cells exhibit a pattern
of gene expression similar to that of human pancreatic islets
(GSE 18821) (Kiselyuk et al., 2010). Accordingly, we conducted a
bioinformatic analysis to compare genes affected by BIM5078 in
T6PNE cells (GSE 33432) and genes affected by genetic deletion
of HNF4a in mouse islets (Gupta et al., 2007). Of the 156 identifi-
able genes altered in HNF4a-deleted islets compared to normal
islets, 20 were exact matches to genes affected by BIM5078. An
additional 36 genes were closely related to genes altered by
HNF4a knockout, (e.g., cyclinD1 and Rab3a versus cyclinD2
and Rab3b, respectively). Using this analysis, 36% of the genes
affected by genetic deletion of HNF4a were either identical ortd All rights reserved
Figure 2. BIM5078 and BI6015 Repress
Insulin Promoter Activity through HNF4a
Antagonism
(A and B) Direct binding was based on quenching
of HNF4a aromatic amino acid fluorescence
emission. Full-length HNF4a protein (100 nM) in
2 ml of PBS was titrated with increasing concen-
trations of BIM5078 (A) or FK614 (B). The data are
presented as the change in fluorescence intensity
(Fo  F) plotted as a function of ligand concen-
tration. Values represent the mean ± SE, n = 3.
Insets, linear plot of the binding curve from each
panel.
(C) DARTS assay. HepG2 cells were treated with
DMSO (lane 1), BI6018 (lane 2), FK614 (lane 3),
BIM5078 (lane 4), or BI6015 (lane 5) at a concen-
tration of 20 mM for 24 hr. Total cell protein was
extracted, and each sample was split into three
aliquots for proteolysis without () or with (+)
subtilisin (left panels) or for Coomassie (In-
stantBlue) staining (middle panels) as a control
to ensure that the compounds did not induce
nonspecific proteolysis. Lane M-MW markers.
Western blots were quantified using ImageJ
software, demonstrating a statistically significant
effect of BI6015 on subtilisin sensitivity. Values
represent the mean ± SE of 3 biological replicates.
*p < 0.05.
(D) Docking of BIM5078 (tan, left panel), BI6015
(violet, left panel), and FK614 (green, right panel) in
the LBD of HNF4a with linoleic acid (cyan) crys-
tallized. The nitro group of BIM5078 and BI6015 is
predicted to form hydrogen bonds with Arg226
and Gly237. In this pose, the aryl chloro (BIM5078)
andmethyl (BI6015) groups occupy a hydrophobic
pocket lined with Leu219, Leu 200 and Met342.
The benzimidazole core occupies the same
hydrophobic pocket as the carbon chain of the
fatty acid.
(E) HNF4a and insulin gene expression were
upregulated when E47 was induced by tamoxifen
in T6PNE, which has a low level of insulin (Kiselyuk
et al., 2010) and HNF4a expression at baseline.
Differences in expression were measured relative
to 0.5 mM tamoxifen by Student’s t test (*p < 0.05,
**p < 0.001).
(F) HNF4a siRNA repressed both exogenous and
endogenous insulin promoter activity in T6PNE
cells. Differences in expression between vehicle
(DMSO or scrambled siRNA) and HNF4a siRNA
were measured by Student’s t test (*p < 0.05,
**p < 0.01). Insulin and HNF4a mRNA levels in (E)
and (F) were normalized to GAPDH.
See also Figure S5.
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HNF4a Antagonistsclosely related to genes affected by pharmacologic inhibition of
HNF4a. A Chi-square analysis showed that T6PNE cells treated
with BIM5078 were statistically similar to the transcriptional
profile of HNF4a genetic deletion (36% intersection, p < 0.0001)
when compared with 50,000 trials of randomly generated gene
sets of the same size selected from genes expressed in T6PNE
cells (11% intersection predicted) (Table S2). The concordance
between the genes affected by genetic deletion and treatment
with BIM5078 is particularly striking given that the analysis was
done in different species (human versus mouse) and different
cell types (the cell line T6PNE cultured in vitro versus primaryChemistry & Biology 19,mouse islets) and that genetic deletion in murine b cells occurred
during embryonic development, as soon as the insulin promoter
became active. In summary, the gene expression data support
that BIM5078 induces pharmacologic antagonism of HNF4a.
BIM5078 Also Affected a Subset of Genes with No
Known HNF4a Binding Sites
To further examine the effects of BIM5078 on gene expression,
we utilized the web-based systems biology software NextBio
to compare lists of genes containing cis-regulatory motifs with
the list of genes modulated by BIM5078. We restricted our806–818, July 27, 2012 ª2012 Elsevier Ltd All rights reserved 809
Figure 3. BIM5078 and BI6015 Affect the
Expression of Known HNF4a Target Genes
(A–C) HNF4a antagonists BIM5078 and BI6015
repress HNF4a gene expression. T6PNE (A), MIN6
(B), and HepG2 (C) cells were cultured for 5 (B)
or 48 (A and C) hr in the presence of BIM5078 or
BI6015. HNF4a mRNA levels were normalized to
18S rRNA (A and C) or GAPDH (b) to control for
nonspecific compound effects. Differences in
expression were measured by Student’s t test
(*p < 0.05, **p < 0.002).
(D) Effect of BI6015 on the OTC promoter. pGL3/
mOTC-235, a plasmid containing the HNF4a-
responsive OTC promoter driving the firefly lucif-
erase gene, was cotransfected into HepG2 and
CV-1 cells with a plasmid encoding full-length
human HNF4a. Cells were treated with DMSO or
1 mM BI6015 for 48 hr. HepG2 cells had greater
baseline stimulation of the OTC-luciferase trans-
gene than CV-1 cells, and BI6015 potently
reduced this baseline activity in both cell lines.
Values represent the mean ± SE, n = 3. Differences
in activity were measured by Student’s t test
(*p < 0.05, **p < 0.001).
(E) Effect of compounds on HNF4a DNA binding.
DNA binding was assessed using the HNF
TransAM ELISA (Active Motif, #46296). Com-
pounds were incubated with HepG2 cells over-
night at the indicated concentration, a condition
that had no effect on HNF4a protein levels (Fig-
ure 1C). Nuclear protein extracts (5 mg) were then
assayed for HNF4a DNA binding activity using an
anti-HNF4a specific antibody. Values represent
the mean ± SD, n = 3 biological replicates. Differ-
ences in activity weremeasured by Student’s t test
(*p < 0.05).
See also Figure S4 and Table S2.
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HNF4a Antagonistsanalysis to the Molecular Signatures Database (MSigDB) con-
taining motif gene sets annotated by the Broad Institute to
enable us to associate changes in our microarray studies with
conserved, putative cis-regulatory elements (Xie et al., 2005).
The most significantly correlated regulatory motifs were the
E12-, AP4-, and MYOD-binding sites, all of which contained
the core CANNTG E-box sequence to which the critical insulin
promoter transactivator E47 binds. It is interesting to note that
there was a significant association with ‘‘HNF4a binding site
gene set 1’’ (containing the motif VTGAACTTTGMMB) but not
four other binding gene sets representing alternate consensus
binding sites for HNF4a, raising the possibility that BIM5078
may affect the activity of HNF4a at some sites preferentially
over others, similar to the effect of other NR ligands on their
target receptors (Hermanson et al., 2002).
Given the effect of BIM5078 on genes containing E-boxes in
their promoter, we compared the genes altered by BIM5078
(GSE 33432) to a set of previously published genes altered by
E47 induction in T6PNE cells (Kiselyuk et al., 2010). Of the 214
genes altered by BIM5078, 67 (31%, p < 0.001) were also altered
by E47 induction (Figure 4a; Table S3). This association was
enhanced when only the genes containing E-boxes were com-
pared. Specifically, of the 96 E-box containing genes altered810 Chemistry & Biology 19, 806–818, July 27, 2012 ª2012 Elsevier Lby BIM5078, 42 (p < 0.001) were also altered by E47 induction
(Figure 4B). Of the 67 genes altered by both BIM5078 and E47
induction in T6PNE, only one (SERPINI1) has been previously
shown to bind HNF4a directly in ChIP-chip studies performed
in islets (Odom et al., 2004).
The effect of BIM5078 on E-box binding in the insulin promoter
prompted us to examine the impact of BIM5078 on other genes
regulated by E-boxes. We have previously shown that the gene
encoding the cyclin-dependent kinase inhibitor p57Kip2,
CDKN1C, is directly regulated by E47 occupation of a particular
E-box within the p57Kip2 CDKN1C promoter (Kiselyuk et al.,
2010). Although the CDKN1C promoter does not contain an
HNF4a-binding site, BIM5078, but not FK614, which does not
act on HNF4a, potently decreased CDKN1C expression in
T6PNE cells (Figure 4C). These results suggest that an important
effect of HNF4a on gene expression occurs through E-box
sequences in the promoters of genes that may or may not
contain HNF4a-binding sites.
BIM5078 Disrupted Binding of E47 and PDX-1
to the Human Insulin Promoter
Although there is a well-characterized binding site for HNF4a in
the rodent insulin gene promoter (Bartoov-Shifman et al.,td All rights reserved
Figure 4. BIM5078 and BI6015 Affect the
Expression and Binding of E47-Responsive
Genes
(A) Microarray data were analyzed using Gene-
Spring GX11. Of 214 genes whose expression
changed with BIM5078 treatment, 67 (p < 0.001)
werealsoalteredby inductionofE47 inT6PNEcells.
(B) Analysis in (A) was restricted to genes with
promoter regions (2 kb, 2 kb) around transcrip-
tion start sites containing E-boxes (CANNTG).
(C) HNF4a antagonists, BIM5078 and BI6015,
reduced Kip2mRNA in T6PNE cells. FK614 had no
effect on Kip2 expression. Kip2 mRNA values are
reported as normalized to 18 s rRNA to control for
nonspecific compound effects. Differences in
expression between vehicle (DMSO) and BIM5078
or BI6015 were measured by Student’s t test
(*p < 0.05, **p < 0.01, NS = no significance).
(D and E) BIM5078 decreases association of E47
and PDX-1 to the human insulin promoter. T6PNE
cells were treated with 1 mM tamoxifen and DMSO
or 5 mM BIM5078 for 48 hr, followed by ChIP with
anti-E47 antibody and anti-PDX-1 antibody.
Q-PCR was performed with primers targeting
E-box and A-box elements in the insulin promoter.
At 48 hr, treatment with BIM5078 significantly
decreased binding of E47 to the distal E-box (E2),
but not to the proximal E-box (E1) (D). Similarly,
BIM5078 decreased binding of PDX-1 to all A-box
elements tested (A1, A3, and A5) on the insulin
promoter (E). Differences in binding between
vehicle (DMSO) and BIM5078 were measured by
Student’s t test (*p < 0.05, **p < 0.01).
See also Table S3.
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HNF4a Antagonists2002), the cognate region of the human insulin promoter varies in
sequence, and HNF4a has not been detected in ChIP-Chip
studies as being directly bound to the human insulin promoter
(Odom et al., 2004). However, there is a well-characterized
HNF1a site in the human insulin promoter (Okita et al., 1999),
suggesting one possible route through which HNF4a can act.
Because of the evidence that HNF4a does not bind directly to
the human insulin promoter, we further investigated the mecha-
nism by which BIM5078 inhibits insulin gene expression. One
possibility was that HNF4a acts indirectly, through effects on
other insulin promoter transactivators. To test this hypothesis,
ChIP assays were used to probe the binding of transcriptional
activators E47 and PDX-1 to their regulatory sequences on the
insulin promoter (i.e., E-box [CANNTG] and A-box [TAAT] motifs,
respectively) in the presence and absence of BIM5078. After
48 hr, treatment with 5mM BIM5078 significantly decreased the
association of E47 with the distal (E2) but not the proximal (E1)
E-box of the insulin promoter (Figure 4D). Furthermore, associa-
tion of PDX-1 was significantly decreased at all tested A-boxes
(Figure 4E). These results are consistent with the hypothesis
that BIM5078-mediated repression of insulin promoter activity
occurs indirectly through disrupted binding of critical transcrip-
tion factors.
Fatty Acids Bound to HNF4a Preferentially Inhibited
the Insulin Promoter
Because of uncertainty in the literature about the role of natural
or synthetic ligands in controlling HNF4a functional activity, weChemistry & Biology 19,sought to determine whether compounds that have previously
been reported to bind HNF4a had potency in our T6PNE assay.
In the absence of exogenously added ligand, MCFAs and LCFAs
were found in the HNF4a ligand-binding pocket in structural
studies of HNF4a purified from bacteria (Dhe-Paganon et al.,
2002; Duda et al., 2004), consistent with fatty acids being the
natural ligands for HNF4a. Recently, linoleic acid was found to
be bound in the LBP of HNF4a in COS-7 cells, as well as in the
livers of fed but not fasted mice, suggesting that it might be
a natural ligand (Yuan et al., 2009). Furthermore, linoleic acid
binding to HNF4a in mammalian cells was slowly reversible
(Yuan et al., 2009), whereas ligand exchange in vitro was shown
to be irreversible. The relatively poor ligand exchange has raised
questions about whether fatty acids are functionally relevant
ligands or whether they play some other role, perhaps stabilizing
the structure of the protein.
On the basis of the widely accepted mechanism of NR regula-
tion, onewould expect binding of the endogenous ligand (linoleic
acid) to its native receptor (HNF4a) to induce changes in HNF4a
functional activity. To test this, a broad spectrum of fatty acids
was assessed for effects on insulin promoter activity. We found
that MCFAs and LCFAs, including the polyunsaturated fatty acid
linoleic acid, inhibited the insulin promoter as measured by
quantitative RT-PCR (Figure 5A), whereas short-chain fatty acids
(SCFAs), such as acetic and butyric fatty acids, which have not
been isolated in the ligand-binding pocket of HNF4a, did not
have an effect on insulin gene expression. The same pattern of
functional activity was observed using GFP+ cells as a measure806–818, July 27, 2012 ª2012 Elsevier Ltd All rights reserved 811
Figure 5. Metabolic Effects of Fatty Acids
and HNF4a Antagonists
(A and B) T6PNE cells were treated with 1 mM
tamoxifen and either fatty acid or vehicle (DMSO)
for 48 hr, at which time cells were harvested for
RNA isolation. Medium- and long-chain fatty
acids, but not short-chain fatty acids, inhibited
insulin gene expression (A) (*p < 0.01, **p < 0.001).
Palmitate induced a dose-dependent decrease in
both insulin and HNF4amRNA level (B) (*p < 0.05).
(C) MIN6 cells were treated with either 0.08 mM
Oleate or 0.02mMPalmitate for 110 days, at which
time insulin and HNF4a mRNA levels were
measured. mRNA levels were normalized to 18 s
rRNA (A) or GAPDH (B and C) to control for
nonspecific compound effects. Values represent
the mean ± SE, n = 3, *p < 0.05.
(D) BI6015 decreased expression of HNF4a (red)
in the liver.
(E) BI6015 induced hepatic steatosis in murine
hepatocytes in vitro and in vivo. Primary murine
hepatocytes were exposed to DMSO or BI6015
(5 mM) for 3 days, followed by fixation and staining
with Oil Red O. BI6015 was injected IP once
per day at either 10 or 30 mg/kg/day. Mice were
sacrificed for analysis of organ histology after
5 days. Liver sections were stained with H&E and
Oil Red O.
(F) Acylcarnitine analysis by GC/MS was per-
formed on cellular extracts of T6PNE cells. Bio-
logical duplicates were analyzed. Values represent
the mean. Inlay depicts the same data beginning
with C4-OH on the x-axis on a different scale to
show less abundant species. Scale bars in (D) and
(E), 100 mm.
See also Figures S2, S3, S6, and S7.
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insulin promoter using that method (Figure S2). The correlation
between fatty acids bound to HNF4a and those that have
a repressive effect on the insulin promoter assay suggests
a functional role for fatty acids in regulating HNF4a activity and
is consistent with a role for HNF4a in b-cell lipotoxicity.
If fatty acids act to inhibit HNF4a function, they should affect
the expression of HNF4a target genes, including HNF4a itself.
Because the transcriptional role of the putative natural ligands
to HNF4a, fatty acids, has remained unclear, we investigated
their ability to modulate HNF4a expression. In T6PNE cells,
where HNF4a gene expression is induced by tamoxifen simulta-
neously with the addition of the putative fatty acid ligand, we
found that 48 hr treatment with palmitate significantly inhibited812 Chemistry & Biology 19, 806–818, July 27, 2012 ª2012 Elsevier Ltd All rights reservedHNF4a mRNA levels (Figure 5B). In
MIN6 cells, oleate and palmitate inhibited
the INS2 and HNF4a genes, but not INS1
(Figure 5C). Interestingly, this effect
occurred only in MIN6 cells subjected to
prolonged fatty acid exposure, consistent
with the much higher levels of insulin and
HNF4a expression in MIN6 compared
with T6PNE, more closely mimicking nor-
mal b cells and the known long time
course of b cell lipotoxicity. Overall, thesedata are consistent with fatty acids being weak HNF4a antago-
nists compared with the more potent synthetic antagonists
described here.
In addition to fatty acids, several other compounds have been
proposed to be HNF4a ligands, including bezafibrate, acyl-
CoA thioesters, 3,3,14,14-tetramethylhexadecanedioic acid
(Medica-16), and 3-methyl-2-nitronaphthofuran (‘‘Compound 5’’)
(Hertz et al., 2001; Le Gue´vel et al., 2009). It has been suggested
that acyl-CoA thioesters, which are the best studied of the
putative ligands, are too large for the HNF4a LBP (Bogan et al.,
2000; Wisely et al., 2002). However, resolving whether fatty
acids or their activated CoA thioester represent the immediate
ligands regulating HNF4a is complicated by fatty acyl CoA
thioester instability in the aqueous media used for HNF4a
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a report that HNF4a itself exhibits thioesterase activity (Hertz
et al., 2005). In our hands, none of these compounds had con-
sistent and robust effects on insulin promoter activity (Figure S3).
Development and Characterization of BIM5078 Analogs
Because of its promising behavior in vitro, pharmacokinetic
studies were performed to evaluate the potential of BIM5078
for in vivo studies. BIM5078 was found to have relatively low
plasma stability, onlymoderatemicrosomal stability (8% remain-
ing after 3 hr and 32% after 1.25 hr, respectively), high binding to
plasma proteins (98% bound after 4 hr), and low solubility
(0.17 mg/ml after 18 hr).
As a result of its unfavorable pharmacokinetic properties,
structural analogs of BIM5078 were examined to overcome
some of these limitations. Replacement of the chloro group of
BIM5078 with a methyl group resulted in BI6015 (2-Methyl-
1-(2-methyl-5-nitrophenylsulfonyl)-1H-benzo[d]imidazole) (Fig-
ure S4). Additionally, we examined changes to the sulfonamide
linker of BIM5078. Replacement of the -SO2- linker with a meth-
ylene gave BI6018, in which the chloro was also replaced with
a hydroxy group (Figure S4). This compound was found to be
inactive in the insulin promoter assay.
BI6015 reduced endogenous insulin gene expression by
50-fold in T6PNE cells (Figure 1E) and strongly repressed
HNF4a gene expression in MIN6 (Figure 3B) and HepG2 cells
(Figure 3C). The ornithine transcarbamoylase (OTC) promoter
has been well characterized as responsive to HNF4a in transient
transfection assays (Inoue et al., 2002). BI6015 inhibited lucif-
erase expression driven by that promoter in both HepG2
cells and CV-1 cells (Figure 3D). Interestingly, BI6015, unlike
BIM5078, was found not to be a PPARg agonist (Figure 1D), sup-
porting the identification of HNF4a rather than PPARg as the
relevant target for the effects of the compounds. Thus, despite
structural similarity between synthetic and natural ligands that
bind PPARg (Tontonoz and Spiegelman, 2008) and those that
bind HNF4a, we found that a structural modification as subtle
as the substitution of a methyl for a chloro group can dissociate
their effects, thereby reducing off-target effects. BI6015 docked
well into the HNF4a LBP (Figure 2D, violet molecule in left panel),
with a GoldScore of 42.1, very similar to that of BIM5078. It
should be noted that the antagonists also dock in the LBP of
the closely related NR HNF4g (Gerdin et al., 2006) (Figure S5).
Although gene expression studies and the high degree of
structural homology of BI6015 with BIM5078 were consistent
with BI6015 also interacting directly with HNF4a as its primary
mechanism of action, it was important to demonstrate this
directly. To accomplish that, we employed a novel assay termed
drug affinity target stability (DARTS) (Lomenick et al., 2009). This
assay takes advantage of the conformation change in a protein
target induced by ligand binding. The conformation change is
detected by a consequent change in the sensitivity to proteol-
ysis. We employed this technique with the HNF4a antagonists
BI6015 and BIM5078, as well as FK614 and BI6018, which
were inactive in all assays that were responsive to HNF4amodu-
lation. As expected for actual ligands, BI6015 and BIM5078
induced altered HNF4a protease sensitivity, with BI6015, the
more potent compound, having a much greater effect, whereas
BI6018 and FK614 had no effect (Figure 2C).Chemistry & Biology 19,NR ligands typically affect the binding of the receptor to DNA.
Thus, we studied the effect of the compounds on HNF4a DNA
binding with an ELISA in which an oligonucleotide containing
an HNF4a-binding site is attached to a plate well. Nuclear
extracts from cells incubated with a particular compound were
added to the wells, and an antibody against HNF4a was then
used to detect binding of HNF4a to the oligonucleotide. Consis-
tent with the gene expression and biochemical studies, BI6015
potently repressed HNF4a DNA binding. BIM5078 was active
but less potent, whereas BI618 and FK614 were inactive
(Figure 3E).
Given the in vitro evidence that BI6015 was a potent HNF4a
antagonist, we tested it for in vivo efficacy. In vivo PK studies
of BI6015 in mice revealed a half-life of approximately 90 min
on delivery by oral gavage or intraperitoneal (IP) injection, with
moderate plasma levels (AUC = 1.6 mg$min/ml after a
30 mg/kg IP injection). In addition, high levels of BI6015 were
found in the liver (3.1 mM at 24 hr after a 30 mg/kg IP injection
in mice). Thus, in addition to improved specificity for HNF4a rela-
tive to other NRs, BI6015 has a more favorable stability profile
over its predecessor, BIM5078, making it suitable for in vivo
studies. In addition, a Ricerca hit profiling panel of 41 recep-
tors/enzymes, including major cytochrome P450s and a number
of NRs, including RXR, showed significant cross reactivity
with only one CYP (2C19), and one L-type calcium channel
(Supplemental Data).
BI6015 Induced Loss of HNF4a Expression and Hepatic
Steatosis In Vivo
Injection of BI6015 into the peritoneum of mice once per day for
5 days at a dose of 30 mg/kg was well tolerated. A VetScan Liver
Panel revealed that blood chemistries, including ALT, were un-
affected by BI6015 treatment, suggesting an absence of hepato-
cellular death in the normal liver (Figure S6). Because HNF4a is
highly expressed in the liver, hepatic tissue was harvested and
examined, along with the intestine and kidney (other sites of
high HNF4a expression).
Consistent with the effects of BIM5078 on HNF4a expression
in vitro, both in human- and murine-derived cell lines, BI6015
induced a loss of HNF4a protein in the liver (Figure 5D), but not
in the intestine or kidney (Figure S7). It is possible that the lack
of effect in the intestine and kidney was due to a high degree
of hepatic first-pass metabolism following IP administration, as
hepatic microsomal stability studies on BI6015 showed that
only 22% of the compound remained after a 60 min incubation
in vitro. Furthermore, no difference in the number of cells ex-
pressing the proliferation marker Ki67 was observed in liver,
intestine, or kidney with BI6015, as compared with vehicle-
treated animals.
Although there was no evidence of hepatocellular death, the
hepatocytes from livers of mice injected with BI6015 exhibited
marked fat accumulation (steatosis) (Figures 5E and 6D), similar
to the effect of genetic deletion of HNF4a in the liver (Hayhurst
et al., 2001). Steatosis and vesicular changes were dose depen-
dent between 10 and 30 mg/kg of BI6015 administered daily or
every other day, as evidenced by increased fat staining with Oil
RedO, but steatosis was limited to regions around vessels, again
consistent with extensive hepatic metabolism limiting the area of
the liver that was exposed to active compound. In vitro, BI6015806–818, July 27, 2012 ª2012 Elsevier Ltd All rights reserved 813
Figure 6. HNF4a Antagonists Are Cytotoxic to Hepatocellular Carcinoma
(A) Toxicity was not observed in primary hepatocytes treated with BI6015 in vitro.
(B) BI6015 was potently toxic to Hep3B-Luc cells, as measured by bioluminescence. Fat accumulation, measured by Oil Red O staining (red), was enhanced in
Hep3B-Luc cells treated with BI6015, while cell division, measured by BrdU uptake (green), was blocked in a dose-dependent manner.
(C) Bioluminescence of Hep3B-Luc treated with BI6015 was quantified at 24, 48, and 72 hr after treatment. Decreased bioluminescence correlated directly with
decreased cell counts.
(D) Hep3B-Luc cells were injected into the liver parenchyma of nude mice, hereafter referred to as human hepatocellular carcinoma (HCC) mice. Animals were
injected IPwith 30mg/kg of BI6015 daily or every other day, as tolerated. Treatment with BI6015 resulted inmarked induction of Oil RedO staining (red) in both the
normal liver and tumor region, as compared with DMSO.
(E and F) Apoptosis was evaluated by immunostaining for cleaved caspase-3 (red) and a TUNEL assay (green). High levels of cleaved caspase-3 expression were
found in the tumor regions, but not in the normal liver of BI6015-treated HCCmice as comparedwith the DMSO control. A similar phenomenon was observedwith
TUNEL-positive cells, which were only found in tumor regions of BI6015-treated HCCmice, predominantly in regions surrounding the necrotic core of the tumor.
Scale bars in (A), (D), (E), and (F), 200 mm (inset for D, 50 mm); scale bar in (B), 100 mm.
See also Figure S8.
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HNF4a Antagonistsinduced steatosis in primary mouse hepatocytes, again without
evidence of cell death (Figure 5E).
BI6015AdministrationResulted inChanges in Fatty Acid
Oxidation
Given the known role of HNF4a in both fatty acid biosynthesis
and utilization (Odom et al., 2004; Palanker et al., 2009), we
studied the effect of BI6015 on fatty acid profiles. Acylcarnitine
profiles of T6PNE cells treated with BI6015 revealed decreased
levels of longer chain acylcarnitines, particularly C18, C18:1,
C16, and C14 (Figure 5F) with a concurrent increase in acetylcar-
nitine. This is consistent with BI6015 acting as an HNF4a antag-
onist and with HNF4a antagonism increasing fatty acid oxidation
(Degrace et al., 2004). However, we also observed that BI6015
induced hepatic steatosis. Together, these results indicate that
hepatic steatosis resulting from BI6015 administration and
supposed HNF4a inhibition cannot be explained by impaired
fatty acid oxidation. A similar phenomenon has been reported
in mice fed the conjugated trans-10, cis-12-isomer of linoleic
acid, in which lipid accumulation is observed despite increases
in fatty acid oxidation (Degrace et al., 2004).
BI6015 Is Cytotoxic to HumanHepatocellular Carcinoma
While studying BIM5078 and BI6015 in vitro, we unexpectedly
noted that they were toxic to a number of different tumor cell
lines but not to cultured primary cells. To further characterize
this phenomenon, we examined the effects of BI6015 on
a variant of the human hepatoma cell line Hep3B that was en-
gineered to express a luciferase transgene under the control of
the CMV promoter, in parallel with primary hepatocytes. BI6015
treatment was markedly toxic to Hep3B cells (Figures 6B and
6C) but spared primary hepatocytes (Figure 6A). These obser-
vations coincided with cell cycle arrest, as evidenced by
decreased BrdU (green) incorporation after 48 hr of treatment
(Figure 6B). Consistent with what we and others have observed
with respect to HNF4a antagonism, perturbations to hepato-
cytes by BI6015 resulted in characteristic steatosis in the
absence of cell death (Hayhurst et al., 2001) (Figure 6D). To
determine the scope of tumor cytotoxicity, BI6015 was
submitted to the developmental therapeutics program (DTP)
at the NCI/NIH, where it was screened in vitro against a panel
of 60 human tumor cell lines. Slowed growth and/or toxicity
were observed with BI6015 treatment on a wide range of
cancer cell lines (Figure S8). Similarly, siRNA to HNF4a also
resulted in toxicity to HepG2 cells and to a greater extent to
T6PNE cells.
To extend the in vitro finding of cytotoxicity to tumor cells
in vivo, we studied the effects of BI6015 treatment in a human
orthotopic xenograft model, in which luciferase-expressing
Hep3B cells were injected directly into the liver parenchyma
(Yao et al., 2003). Once the tumor was established, as defined
by a doubling of luciferase counts on three consecutive reads
by bioluminescent imaging, the animals were injected IP with
30 mg/kg of BI6015 daily or every other day, as tolerated. After
20–57 days of treatment, the tumors and normal liver samples
were harvested and analyzed. There was a marked induction
of Oil Red O staining in both the normal liver and tumor samples,
although the background level of Oil RedO in the tumor cells was
high (Figure 6D). Interestingly, the distribution of the steatoticChemistry & Biology 19,cells was limited, being restricted to areas around the hepatic
blood vessels (Figure 6D).
Within the tumor, but not in the normal liver, there were regions
with high levels of apoptotic cells positive for TUNEL and cleaved
caspase-3 (Figures 6E and 6F). Although some treated animals
exhibited decreased luciferase counts, this did not occur in all
animals. Higher doses of BI6015 could not be delivered because
of limited solubility of the compound.
DISCUSSION
HNF4a is an attractive target for pharmacologic manipulation.
Not only is it at the center of multiple complex feedback loops
that maintain differentiated function in the pancreas and liver,
but HNF4a has also been implicated in a number of disease
states, including diabetes, inflammatory bowel disease, cancer,
and others. Here, we report the discovery of small-molecule
inhibitors of HNF4a that help interrogate and clarify complex
processes driven by HNF4a-dependent pathways.
Until about a decade ago, HNF4a was considered to be an
orphan receptor. Structural studies identified tightly bound fatty
acids in the LBP of HNF4a, which existed in a mixture of active
and inactive conformations, suggesting that the fatty acids
were playing a structural role, rather than inducing a specific
conformational change (Dhe-Paganon et al., 2002; Wisely
et al., 2002). Affinity isolation followed by mass spectrometry
(AIMS) was used more recently to reveal that linoleic acid (LA,
C18:2u6) was bound to HNF4a in the livers of fed but not fasted
mice, suggesting that ligand binding could be reversible (Yuan
et al., 2009). These results were also consistent with findings in
Drosophila species showing that a GAL4-dHNF4 ligand sensor
could be activated by starvation or administration of exogenous
LCFAs (Palanker et al., 2009). However, the study by Yuan et al.
did not find evidence of a significant effect of ligands on HNF4a
transactivation. In contrast, we found that MCFAs and LCFAs,
including the polyunsaturated fatty acid linoleic acid, antago-
nized the insulin promoter, whereas shorter chain fatty acids,
which have not been found in the LBP of HNF4a (Dhe-Paganon
et al., 2002), did not. Our ability to observe effects of fatty acids
on HNF4a activity in T6PNE cells may be because HNF4a
expression is induced in those cells by tamoxifen simultaneously
with the addition of fatty acids.
The observed correlation between fatty acids that have been
found to be bound to HNF4a and those that have a repressive
effect on the insulin promoter assay, together with evidence
that HNF4a expression is inhibited by fatty acids, suggests
that fatty acids are weak HNF4a antagonists. This is consistent
with the finding that linoleic acid inhibited HNF4a protein expres-
sion (Yuan et al., 2009). The finding that fatty acids antagonize
HNF4a activity may provide insight into the mechanism by which
fatty acids exert their biological effects (e.g., in b cell lipotoxicity
as well as other disorders in which there are high circulating
levels of fatty acids).
On the basis of the data presented, we believe that BIM5078
and BI6015 act as HNF4a antagonists by binding directly in the
LBP. This thinking is supported by our biochemical data showing
tight binding, although we cannot use those results to dif-
ferentiate orthosteric from allosteric interactions. BIM5078 and
BI6015 are structurally similar to FK614, a knownPPARg agonist,806–818, July 27, 2012 ª2012 Elsevier Ltd All rights reserved 815
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strongly indicating that the compound binds within the PPARg
LBP. FK614 bound poorly to HNF4a and was inactive in all of
the assays for effects on HNF4a activity. Of particular interest,
PPARg andHNF4a, both ofwhich are affected byBIM5078, share
fatty acids as their natural ligands. This provides support that
BIM5078 and BI6015 are HNF4a ligands. Consistent with that,
our docking experiment shows that BIM5078 and BI6015 have
binding poses that are similar to the fatty acids observed in
HNF4a crystal structures. The effect of BIM5078, acting as an
antagonist of HNF4a and an agonist for PPARg, is similar to that
of fatty acids thatpotentlyactivatePPARg,whereasweandothers
found them to inhibit HNF4a (Yuan et al., 2009). Regardless, the
atomic details of BIM5078 and BI6015 interaction with HNF4a
are yet to be revealed and depend on the development of ligands
with improved solubility to enable future structural work.
Genetic deletion ofHNF4a in pancreatic b cells did not result in
loss of insulin gene expression (Gupta et al., 2007), in contrast to
our results with T6PNE cells that displayed high sensitivity to
small-molecule modulation of HNF4a activity and enabled
discovery of viable antagonists in the short time frame in which
high-throughput screening is performed. We show that HNF4a
not only appears to act on a number of target genes through
effects on E47, which we induced at a submaximal level in
T6PNE for the screening purposes, but it is also induced by
E47 expression, a previously unknown mechanism of HNF4a
transcriptional regulation. This suggests that HNF4a and E47
form a multicomponent regulatory network involving complex
feedback loops, similar to what has been described for the inter-
action between HNF4a and HNF1a (Odom et al., 2004). We think
that it is this relationship between E47 and HNF4a that renders
the insulin promoter in T6PNE cells susceptible to HNF4amodu-
lation, affording us the opportunity to discover compounds that
antagonized HNF4a activity.
The effect of HNF4a antagonists on E-box-containing genes
was unexpected, because the vast majority of these genes are
not known to contain HNF4a-binding sites and do not bind to
HNF4a in ChIP-Chip assays (Odom et al., 2004). However,
a similar phenomenon was reported for the human intestinal
cell line Caco-2, in which two-thirds of the genes that bound
HNF4a in their ChIP-Chip assay had no discernable HNF4a-
binding site (Boyd et al., 2009). Classically, NRs exert their
effects by binding to highly conserved DNA-binding elements,
but it is known that NRs can also act indirectly via tethering to
target genes (Adler et al., 1988). NR tethering has been reported
to occur through a number of DNA binding transcription factors,
including members of the bHLH class including E47 (Murayama
et al., 2004) and the homeodomain class (Stender et al., 2010).
On the human insulin promoter, which does not contain an
HNF4a-binding site and does not bind to HNF4a in ChIP-Chip
assays (Odom et al., 2004), we found that binding of both E47
and PDX1 was inhibited by BIM5078, which we propose to be
an HNF4a antagonist. On the p21 promoter, HNF4a was shown
to act through a DNA binding independent mechanism involving
binding to the bHLH factor c-myc (Hwang-Verslues and Sladek,
2008). Altogether, these results suggest a model in which HNF4a
is recruited to a transcriptional complex bound to DNA in
a ligand-dependent manner, but might not necessarily involve
direct binding of HNF4a to DNA.816 Chemistry & Biology 19, 806–818, July 27, 2012 ª2012 Elsevier LWhile studying the effect of BIM5078 and BI6015 in vitro, we
noticed marked toxicity in a variety of tumor cell lines but not in
cells cultured from primary tissue. HNF4a has previously been
described to have a role in tumor pathogenesis, but the studies
are conflicting, with both upregulation and downregulation of
HNF4a expression being reported in association with tumor
progression. Knockdown of HNF4a mRNA by siRNA has been
shown to inhibit growth and proliferation of colorectal cancer
cells in vitro (Schwartz et al., 2009). This is consistent with reports
that have shown that HNF4a is upregulated in human hepatocel-
lular carcinoma (Xu et al., 2001). However, others have shown
that downregulation of HNF4a promotes tumorigenesis in hepa-
tocellular and other cancers (Ning et al., 2010).
Several lines of evidence suggest that the effects of BI6015 on
transformed cells are mediated through HNF4a. First, we de-
tected marked toxicity with selective HNF4a knockdown by
siRNA. Furthermore, the concentration at which BI6015 induced
cytotoxicity was very similar to that at which it affected the
expression of downstream targets of HNF4a. This would not
be expected if the effects on cancer cells were caused by an
off-target effect.
In vivo, BI6015 caused dose-dependent hepatic steatosis in
normal hepatocytes and in Hep3b xenografted cells. This is
consistent with the effects of genetic ablation of HNF4a (Hay-
hurst et al., 2001). Importantly, the induction of steatosis pro-
vided a biomarker for where the compound was acting, which
appeared to be restricted to regions surrounding blood vessels.
Apoptosis was induced in Hep3b cells but not in primary hepa-
tocytes, consistent with the in vitro results. Of note, apoptotic
cells also were distributed in a perivascular pattern, mimicking
that of steatosis. The lack of activity of BI6015 distal to the
vessels suggests either poor tissue penetration, as has been
shown for a number of chemotherapeutics including doxorubicin
(Minchinton and Tannock, 2006), or extensive hepatic metabo-
lism that limits the amount of active compound to regions
surrounding vessels. The in vitro pharmacology with hepatic
microsomes suggests that extensive hepaticmetabolism is likely
to be occurring in vivo, supporting the need for additional medic-
inal chemistry to develop more stable molecules. We think that
the limited in vivo efficacy in the Hep3B orthostatic xenograft
model could have been due to a high degree of hepatic metab-
olism, thereby restricting the amount of drug that penetrated into
the tumor, which would be consistent with steatosis in both
normal liver and tumor samples being localized to the region
around blood vessels. Nonetheless, our data indicate that
BIM5078 and BI6015 might be promising agents, and HNF4a
a promising target, for cancer therapy. In addition, these
compounds provide powerful tools for studying the function of
HNF4a. Additional studies will be required to determine whether
an appropriate balance between the antitumor effects of HNF4a
and the side effects of inhibiting HNF4a (e.g., hepatic steatosis)
can be achieved. The fact that mice administered BI6015 for up
to a month have tolerated it well raises the hope that this will be
the case.
SIGNIFICANCE
HNF4a is a member of the NR class of transcription factors.
This family has 48 members in humans and is characterizedtd All rights reserved
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a wide range of processes in which it is desirable to have a
small molecule regulate a gene expression program. As
such, NRshave been highly desirable pharmacologic targets.
However, many have yet to be characterized in terms of the
nature of the endogenous ligand and/or the development of
synthetic ligands that can be used pharmacologically. One
of thosehasbeenHNF4a,whichplaysacentral role incontrol-
ling gene expression in the liver, pancreas, kidney, and in-
testine. Here, we describe two compounds, BIM5078 and
BI6015, and present evidence that they are HNF4a antago-
nists. As expected, the antagonists repressed known
HNF4a targetgenes.Surprisingly, thecompoundswere found
to be selectively cytotoxic to transformed cells, raising the
possibility that they might be useful for cancer therapy.
EXPERIMENTAL PROCEDURES
Cell culture, compound library screening, and confirmatory assays, including
RT-PCR, are described in (Kiselyuk et al., 2010). Detailed methods are pre-
sented in the Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures, three tables, Supplemental
Data, and Supplemental Experimental Procedures and may be found with
this article online at http://dx.doi.org/10.1016/j.chembiol.2012.05.014.
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